GE Medical Systems and Amersham Health (formerly Nycomed Amersham Imaging) have inked a broad research agreement to develop new PET-based molecular diagnostic imaging technologies and systems.
The first joint project of Waukesha, WI-based GE and Princeton, NJ-based Amersham will be the development of a PET synthesis system to produce a new generation of targeted molecular radiopharmaceuticals. Current PET synthesis systems that interface with cyclotrons generate just one diagnostic radiopharmaceutical, usually FDG.
Amersham and GE are pursuing development of noninvasive molecular imaging products to detect disease with specific molecular markers. The goal is to create a "chemistry lab" that can output a number of PET diagnostics with high disease specificity.
By AuntMinnie.com staff writers
November 30, 2001
Related Reading
ADM signs with GE for PET and fused imaging systems, November 27, 2001
PET offers important benefits in breast cancer imaging, October 29, 2001
Amersham renames Nycomed Amersham Imaging, October 15, 2001
GE finalizes Coincidence Technologies purchase, October 4, 2001
Copyright © 2001 AuntMinnie.com
